Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized...

Area of Science:

• Endocrinology
• Immunology
• Clinical Pharmacology

Background:

• Thioredoxin-interacting protein (TXNIP) overexpression in pancreatic beta cells leads to apoptosis and is implicated in glucotoxicity.
• Calcium channel blockers (CCBs) have shown potential in mitigating these effects, suggesting a role in beta cell preservation for type 1 diabetes.

Purpose of the Study:

• To evaluate the efficacy of verapamil, a CCB, in preserving pancreatic beta cell function in pediatric and adolescent patients newly diagnosed with type 1 diabetes.

Main Methods:

• A double-blind, randomized clinical trial involving 88 participants (aged 7-17 years) with newly diagnosed type 1 diabetes.
• Participants received either daily oral verapamil or a placebo for 52 weeks.
• The primary outcome measured was the change in C-peptide levels (a marker of beta cell function) via a mixed-meal tolerance test.

Main Results:

• Verapamil treatment resulted in a 30% higher stimulated C-peptide level at 52 weeks compared to placebo (0.65 vs 0.44 pmol/mL).
• A significantly higher percentage of participants on verapamil (95%) maintained a C-peptide level of ≥0.2 pmol/mL compared to the placebo group (71%).
• Hemoglobin A1c levels were comparable between groups, and adverse events were similar.

Conclusions:

• Verapamil demonstrated a partial preservation of stimulated C-peptide secretion in children and adolescents with type 1 diabetes over 52 weeks.
• Further research is warranted to assess the long-term durability of these effects and to establish optimal treatment durations.